Mentors-in-Residence

As Partner on the Pfizer Ventures team and Executive Director in the Emerging Science and Innovation group, Mike has responsibility for growing venture investment transactions and managing equity investments aligned with future directions of Pfizer.

Bob has over 30 years of experience in oncology drug discovery and early development from target validation through clinical proof of concept. 

Tanya has spent over a decade helping companies in the Biotech and Pharmaceutical industries develop their technology and drug pipelines. Her roles in the Pharmaceutical industry have spanned from R&D consulting at a top global boutique consulting firm in NYC, to launch planning, and global business insights and competitive intelligence.

Stephen is a human geneticist with over 32 years of commercial experience in life sciences in areas of stem cells, cell and gene therapy and drug development. He is an entrepreneur, teacher and scientific and business leader in life science with specific emphasis on small company startups and non-profits.

Al is an entrepreneurial, high energy, and accomplished executive with broad experience in scientific, technological, and business leadership – building, creating, and sustaining cultures of innovation within fast-paced, high-growth, agile, and productive environments. He is a unique visionary with passion for excellence and innate ability to set and communicate vision, mission, and strategy to technical and non-technical audiences alike.

Bruce has over 20 years of experience as the President and CEO of publicly and privately held development stage biotechnology companies and manufacturers. He has negotiated licenses and sales agreements, has in-licensed technologies and sponsored research projects with major universities across North America and has participated in the acquisition and divestiture of product lines and companies. Bruce has also helped to raise tens of millions of dollars in equity financing.

Peter is a resourceful, results driven leader with 20+ years of experience in general management, drug development and business development. He has a strong business and technical experience in bio-pharmaceutical environments. Peter has previously helped North American universities in marketing unlicensed technologies, mentoring faculty and emerging life science companies in business planning, IP portfolio management, grant applications, fundraising and general management.

Ken is an active biotech investor and entrepreneur, successfully creating and managing partnerships, acquisitions, management teams, and launching IPOs for several biotech companies, including Nova, Genaissance, and Chromocell.

Jon has held engineering positions at DuPont and multiple positions at start-up companies, including co-founding and successfully commercializing the Nima Sensor, a food allergen sensing platform. He spent over six years as a Managing Scientist at Exponent providing scientific solutions in a variety of areas, such as materials, sensors, risk assessment, and technical due diligence.

Zvi is a senior academic leader and an experienced global pharmaceutical – biotechnology executive. He leverages a diversified background in big-pharma senior management, biotech startup creation and academia. Zvi has served as a board member of the New Jersey Bioscience Center Incubator since 2010. From 2005 to 2020, he was a board member of the Jerusalem College of Technology.

Dr. Mintz has been a pioneer in the discovery of splice variants and an inventor of more than 50 U.S. and international patents. She is the founder and owner of DiaLean Ltd., and co-founder and principal of Biocceleration Inc.

Reginald has extensive experience in product lifecycle management from conceptual development through design development to industrialization and commercialization, focused on biologics, utilizing drug delivery systems and medical devices.

Ron leads Strategic Bio Insights, a consultancy providing actionable recommendations through competitive intelligence and market intelligence on medical devices, pipeline therapeutics, nanotechnology, devices and biotechnology since 2007. Among his other major engagements is his role as a QED Business Advisor, University City Science Center, successfully securing milestone-based funding of four medical device ventures for market-driven prototype development and pre-clinical proof-of-concept studies

Christopher has over 30 years experience in the pharmaceutical and biotechnology industry. Christopher has been Soligenix's President and Chief Executive Officer and a director since August 2006. He also served on the board of directors for the Alliance for BioSecurity and for the Biotechnology Council of NJ (BioNJ), where he is currently Chair.

Adrienne is a retired BioPharma executive now serving as a Science and Technology Advisor and Mentor. She has over 35 years of experience in natural products research, analytical and bioanalytical chemistry, drug discovery and regulated pharmaceutical development.

Wayne is the principal of Pharmatech Solutions LLC, a consultancy that provides strategic planning, M&A advisory and business development services to pharmaceutical, nutrition and personal care industries. Over the last 20 years, he has held senior level positions at major global corporations, as well as venture back start-ups. He has played a key role in multiple acquisitions with total value of ~$4 billion. 

Peter is a life-science industry consultant with over 35 years’ experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager at multinationals like Abbott and Glaxo as well as biotech start-ups. In the mid-1990s, he led the global introduction of combination HIV therapy for Glaxo Wellcome while keying industry leadership on global treatment access.